MCL Featured Stories
Strategic Lab Collaborations help Mayo Clinic Laboratories accelerate innovation and expand access to advanced diagnostics.
Explore how different types of psychological safety help people move from feeling included to confidently contributing to respectfully challenging ideas.
Due to the Thanksgiving holiday (recognized on Thursday, November 26), Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered.
This program reviews urine drug testing for stimulants and phencyclidine (PCP), with an emphasis on the advantages and limitations of traditional immunoassays and targeted mass spectrometry-based screening.
Register now – Dec. 9, 2025 | This webinar will highlight federal and state regulatory updates affecting hospital laboratory outreach programs, including billing, reimbursement, and government enforcement.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss the future of diagnostics. Later, Eric Hsi, M.D., chair of Mayo Clinic’s Department of Laboratory Medicine and Pathology in Rochester, shares how the department is advancing innovation and helping transform healthcare through laboratory medicine.
REGISTER NOW - This presentation examines how autonomous robotic phlebotomy could transform blood collection. It reviews preanalytic challenges, high-opportunity use cases, clinical findings, and Mayo Clinic human-factors research, with a focus on specimen quality, patient acceptance, workflow, workforce models, and human oversight.
A glossary of essential reimbursement terms to help laboratories improve claims, understand coverage, and forecast revenue.
Building on decades of leadership in autoimmune dysautonomia research, Mayo Clinic Laboratories has enhanced its dysautonomia antibody evaluation with a more sensitive, live cell-based flow cytometry method. The streamlined panel focuses on clinically relevant autoantibodies, providing physicians with actionable insights for diagnosis, prognosis, and treatment planning.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss Mayo Clinic’s new collaboration with Thermo Fisher and the latest on the Protecting Access to Medicare Act (PAMA). Later, Dr. Pritt welcomes Matt Binnicker, Ph.D., Mayo Clinic Laboratories’ chief scientific officer and a leader in novel diagnostics for viral infections, to explore seasonal virus activity.
Review how problem-solving methods can work together to define and measure a problem, identify root causes, test potential solutions, and sustain successful improvements.
This microlearning reviews myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), with a focus on the 2023 International MOGAD Panel diagnostic criteria.
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH) have announced a strategic investment and collaboration aimed at expanding access to advanced diagnostics and precision medicine across Southeast Asia, Australia and New Zealand.